NEA Management Company’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $50.4M | Hold |
1,058,570
| – | – | 2.86% | 12 |
|
|
2025
Q4 | $55.5M | Hold |
1,058,570
| – | – | 2.83% | 12 |
|
|
2025
Q3 | $68.6M | Sell |
1,058,570
-529,284
| -33% | -$30.4M | 3.76% | 8 |
|
|
2025
Q2 | $77.2M | Hold |
1,587,854
| – | – | 5.81% | 5 |
|
|
2025
Q1 | $54M | Hold |
1,587,854
| – | – | 4.16% | 8 |
|
|
2024
Q4 | $62.5M | Hold |
1,587,854
| – | – | 3.53% | 9 |
|
|
2024
Q3 | $74.6M | Hold |
1,587,854
| – | – | 4.06% | 8 |
|
|
2024
Q2 | $85.8M | Hold |
1,587,854
| – | – | 6.45% | 6 |
|
|
2024
Q1 | $180M | Hold |
1,587,854
| – | – | 11.2% | 2 |
|
|
2023
Q4 | $99.4M | Hold |
1,587,854
| – | – | 6.62% | 6 |
|
|
2023
Q3 | $72.1M | Hold |
1,587,854
| – | – | 5.57% | 5 |
|
|
2023
Q2 | $89.1M | Hold |
1,587,854
| – | – | 6.8% | 4 |
|
|
2023
Q1 | $71.8M | Hold |
1,587,854
| – | – | 4.96% | 7 |
|
|
2022
Q4 | $64.5M | Sell |
1,587,854
-2,148
| -0.1% | -$114K | 3.63% | 10 |
|
|
2022
Q3 | $104M | Hold |
1,590,002
| – | – | 5.19% | 6 |
|
|
2022
Q2 | $96.6M | Hold |
1,590,002
| – | – | 4.96% | 5 |
|
|
2022
Q1 | $366M | Hold |
1,590,002
| – | – | 10.56% | 4 |
|
|
2021
Q4 | $120M | Hold |
1,590,002
| – | – | 2.44% | 8 |
|
|
2021
Q3 | $178M | Hold |
1,590,002
| – | – | 2.11% | 7 |
|
|
2021
Q2 | $257M | Hold |
1,590,002
| – | – | 3.35% | 4 |
|
|
2021
Q1 | $194M | Hold |
1,590,002
| – | – | 4.35% | 6 |
|
|
2020
Q4 | $243M | Hold |
1,590,002
| – | – | 6.43% | 4 |
|
|
2020
Q3 | $133M | Sell |
1,590,002
-500,676
| -24% | -$44.4M | 5.63% | 4 |
|
|
2020
Q2 | $154M | Hold |
2,090,678
| – | – | 6.18% | 6 |
|
|
2020
Q1 | $88.7M | Hold |
2,090,678
| – | – | 4.63% | 7 |
|
|
2019
Q4 | $127M | Hold |
2,090,678
| – | – | 6.02% | 5 |
|
|
2019
Q3 | $85.7M | Hold |
2,090,678
| – | – | 7.1% | 4 |
|
|
2019
Q2 | $98.5M | Hold |
2,090,678
| – | – | 6.9% | 4 |
|
|
2019
Q1 | $74.7M | Hold |
2,090,678
| – | – | 3.88% | 8 |
|
|
2018
Q4 | $59.7M | Hold |
2,090,678
| – | – | 2.37% | 9 |
|
|
2018
Q3 | $92.7M | Hold |
2,090,678
| – | – | 4% | 8 |
|
|
2018
Q2 | $123M | Sell |
2,090,678
-1,393,786
| -40% | -$79.4M | 5.76% | 7 |
|
|
2018
Q1 | $159M | Buy |
3,484,464
+263,736
| +8% | +$10.9M | 7.08% | 2 |
|
|
2017
Q4 | $75.6M | Hold |
3,220,728
| – | – | 3.13% | 10 |
|
|
2017
Q3 | $57.6M | Hold |
3,220,728
| – | – | 2.02% | 12 |
|
|
2017
Q2 | $51.6M | Hold |
3,220,728
| – | – | 1.88% | 11 |
|
|
2017
Q1 | $70.1M | Hold |
3,220,728
| – | – | 2.44% | 7 |
|
|
2016
Q4 | $65.3M | Buy |
+3,220,728
| New | +$60.2M | 2.59% | 8 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
NEA Management Company's CRSP Position: Q1 2026 in Review
NEA Management Company held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 1,058,570 shares worth $50.4M. The position accounts for 2.86% of the portfolio, ranked #12.
NEA Management Company first reported a position in CRSP in Q4 2016 and has held it in 38 quarters since. The position peaked at $366M in Q1 2022. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- NEA Management Company held 1,058,570 shares of CRISPR Therapeutics worth $50.4M as of Q1 2026.
- NEA Management Company left its CRISPR Therapeutics share count unchanged in Q1 2026.
- CRISPR Therapeutics made up 2.86% of NEA Management Company's portfolio in Q1 2026, its #12 holding.
- NEA Management Company first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 38 quarters since.
- NEA Management Company's CRISPR Therapeutics position peaked at $366M in Q1 2022.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on NEA Management Company's 13F filing for Q1 2026, filed 15 May 2026.